NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Version of matrix of consultees and commentators reviewed: Provisional matrix of consultees and commentators sent for consultation								
Summary of comments, action taken, and justification of action:								
	Proposal:	Proposal made by:		Action taken: Removed/Added/Not included/Noted	Justification:			
1.	Add the Association of Directors of Public Health to the list of commentators	NHS Cornwall and Isles of Scilly, NHS Dudley & Commissioning Support Appraisals Service		Added	The Association of Directors of Public Health meets the inclusion criteria and has therefore been added to the matrix as a professional group			

National Institute for Health and Clinical Excellence

Consultation comments on the matrix for the technology appraisal of erlotinib monotherapy for the maintenance treatment of advanced or metastatic non-small cell lung cancer

Issue date: November 2009

2	British Oncology Pharmacists Association (BOPA) needs to be added to the matrix.	Eli Lilly and Company Limited	Noted	The British Oncology Pharmacists Association have requested to remain off all matrices, they are already represented by the organisation Cancer Networks Pharmacists Forum.
3.	Commissioning Support Unit – Appraisals	NICE Secretariat	Noted/Amended	Commissioning Support Unit – Appraisals have changed their organisation name to Commissioning Support Appraisals Service, the matrix has been updated to reflect this change.

Consultation comments on the matrix for the technology appraisal of erlotinib monotherapy for the maintenance treatment of advanced or metastatic nonsmall cell lung cancer Issue date: November 2009